We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge Invalidates Ampyra Patents, Clearing Path for Early Generics
Judge Invalidates Ampyra Patents, Clearing Path for Early Generics
Four major patents for Acorda Therapeutics’ successful MS treatment Ampyra were invalidated by a federal judge nearly a decade before they were set to expire — not a month after they were upheld by the PTO.